The treatment of portal hypertension: A meta-analytic review

Hepatology

Volumn 22, Issue 1, 1995, Pages 332-354

  D'Amico, Gennaro ^a   Pagliaro, Luigi ^a   Bosch, Jaime ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; NADOLOL; OCTREOTIDE; PROPRANOLOL; RANITIDINE; SCLEROSING AGENT; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS TRANSECTION; ESOPHAGUS VARICES BLEEDING; HEMODYNAMICS; HEMOSTASIS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIA; LIGATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; META ANALYSIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SHUNTING; SUBLINGUAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

CLINICAL TRIALS; HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; RECURRENCE; RISK FACTORS; VARICOSE VEINS;

EID: 0029134073     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90388-7     Document Type: Article

References (238)

1. A 20-year prospective study of cirrhosis
2. Survival and prognostic indicators in compensated and decompensated cirrhosis
3. Hemodynamic evaluation of patients with intrahepatic portal hypertension: relationship between bleeding varices and the portohepatic gradient
4. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis
5. Portal pressure, presence of gastroesophageal varices and variceal bleeding
6. Aspects of natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisolone
7. Natural history of cirrhosis
8. Incidence of large esophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding
9. Predictive value of ultrasonography in the screening of non-ascitic cirrhotic patients with large varices
10. Complications of endoscopic injection sclerotherapy: a review
11. Sucralfate for the prevention of early rebleeding following injection sclerotherapy for oesophageal varices
12. The natural history of esophageal varices
13. Prevention of first bleeding in cirrhosis
14. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices
15. History of nonalcoholic cirrhosis
16. A clinical investigation of the portacaval shunt. II. Survival analysis of the prophylactic operation
17. A controlled trial of the prophylactic portacaval shunt
18. Prophylactic portacaval anastomosis
19. Reliability of endoscopy in the assessment of variceal features
20. Gastroesophageal endoscopic features in cirrhosis
21. Prediction of variceal hemorrhage by esophageal endoscopy
22. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
23. Clinical-hemodynamic correlations during pharmacological prevention of variceal rebleeding in cirrhosis
24. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices
25. Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage
26. The natural history of esophageal varices in patients with alcoholic liver disease
27. Prospective validation of two indexes of first variceal bleeding
28. Hemodynamic factors in the development and rupture of esophageal varices: a pathophysiologic approach to treatment
29. Endoscopic measurement of variceal pressure in patients with cirrhosis
30. Prognostic factors in upper G.I. bleeding
31. A predictive model for very early rebleeding from varices
32. The course of patients after variceal hemorrhage
33. Definition of death in relation to variceal bleeding
34. Six-week prognostic indicators in upper gastrointestinal hemorrhage in cirrhosis
35. Systemic and hepatic hemodynamics after variceal hemorrhage: effects of propranolol and placebo
36. Assessment of the risk of bleeding from varices by continuous monitoring of portal pressure
37. Prognostic factors for short-term in variceal bleeding
38. Prediction of outcome following acute variceal hemorrhage
39. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient
40. Therapeutic controversies and randomized controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis
41. Risk factors for hemorrhage from oesophageal varices and acute gastric erosions
42. Definitions, methodology and therapeutic strategies in portal hypertension
43. Overview of randomized trials of diuretics in pregnancy
44. Considerations for the meta-analysis of randomized clinical trials
45. Prophylactic portacaval anastomosis in cirrhotic patients with esophageal varices
46. Improved survival after prophylactic portal nondecompression surgery for esophageal varices: a randomized clinical trial
47. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension
48. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis
49. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices
50. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study
51. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis
52. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients
53. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo
54. Propanolol in the prevention of the first hemorrhage from oesophageal varices: results of a randomized double blind cooperative clinical trial
55. Prophylaxis of first hemorrhage from oesophageal varices by sclerotherapy, propranolol or both in cirrhotic patients
56. A randomized controlled trial for the prevention of the first upper gastrointestinal bleeding due to portal hypertension in cirrhosis: sclerotherapy or propranolol versus control groups
57. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients
58. β-adrenergic-antagonists in the prevention of first gastrointestinal bleeding in patients with cirrhosis and oesophageal varices
59. Propranolol for prevention of first esophageal variceal hemorrhage (EVH); a lifetime commitment?
60. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices: a prospective controlled randomized trial
61. Prophylactic endoscopic sclerotherapy of oesophageal varices: a prospective controlled trial
62. Prophylactic sclerosing of esophageal varices: results of a prospective controlled study
63. Prophylactic endoscopic sclerotherapy of esophageal varices
64. Prophylaktische oesophagusvarizen sklerosierung
65. Prophylactic sclerotherapy of large esophageal varices
66. Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis
67. Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial
68. Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis
69. Prophylactic sclerotherapy in nonalcoholic liver cirrhosis: preliminary results of a prospective controlled randomized trial
70. Prophylactic sclerotherapy for esophageal varices: long term results of a single-center trial
71. Prophylactic sclerotherapy for esophageal varices in alcoholic liver disease a randomized single-blind multicenter clinical trial
72. Prophylactic sclerotherapy (ST) in high risk cirrhotics selected by endoscopic criteria
73. Prophylactic sclerotherapy: a controlled study
74. A randomized trial comparing prophylactic (ps) and therapeutic endoscopic sclerotherapy (ts) in cirrhotic patients with large esophageal varices and no previous hemorrhage
75. Prophylactic sclerosis of esophageal varices (EV). Prospective trial
76. β-blockers for prophylaxis of first variceal hemorrhage
77. A meta-analysis of prophylactic endoscopic sclerotherapy for esophageal varices
78. Effect of intravenously administered posterior pituitary extract on hemorrhage from bleeding esophageal varices
79. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective controlled clinical trial
80. Selective intra-arterial vasopressin infusion for upper gastrointestinal tract hemorrhage
81. Continuous intravenous vasopressin in active upper gastrointestinal bleeding
82. Control of bleeding varices by vasopressin: a prospective randomized study
83. Traitement pour la pitressin des hemorragies pour rupture de varices oesophagiennes chez le cirrhotique
84. A controlled comparison of continuous intraarterial and intrvenous infusion of vasopressin in hemorrhage from esophageal varices
85. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension
86. Controlled trial of vasopressin plus nitroglycerin vs vasopressin alone in the treatment of bleeding esophageal varices
87. A randomized trial of vasopressin plus nitroglycerin in the control of acute variceal hemorrhage
88. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial
89. Vasopressin analogs in portal hypertension: different molecules but similar questions
90. Terlipressin in bleeding esophageal varices
91. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding
92. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices
93. Early administration of terlipressin plus transdermal nitroglycerin of active upper gastrointestinal hemorrhage in cirrhotic patients
94. Controlled trial of terlipressin (“glypressin”) versus vasopressin in the early treatment of esophageal varices
95. A randomized trial of triglycyllysine vasopressin versus lysine vasopressin in active cirrhotic variceal hemorrhage
96. A randomized controlled study of triglycyl-vasopressin and vasopressin plus nitroglycerin in the control of acute esophageal variceal hemorrhage
97. A controlled study of glypressin versus vasopressin in the control of bleeding from esophageal varices
98. Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis
99. Terlypressin and endoscopic sclerotherapy control variceal bleeding and prevent early rebleeding in cirrhotic patients
100. Prospective comparison of glypressin, tamponade and their association in the treatment of bleeding esophageal varices
101. A randomized trial of terlipressin plus nitroglycerin vs balloon tamponade in the control of acute variceal hemorrhage
102. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial
103. Terlipressin vs somatostatin in bleeding esophageal varices: a controlled double blind study
104. Double blind comparison of somatostatin infusion vs glypressin injection in the treatment of acute variceal haemorrhage in patients with cirrhosis
105. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver
106. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices
107. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding
108. La somatostatina nel trattamento dell'emorragia da varici esofago-gastriche
109. Comparison of somatostatin and cimetidine in the treatment of acute esophageal variceal bleeding
110. Comparison of intravenous somatostatin and vasopressin infusion in treatment of acute variceal hemorrhage
111. A prospective randomized controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage
112. Effect of somatostatin in controlling bleeding from esophageal varices
113. Eficacia terapéutica de la somatostatina versus vasopressina más nitroglycerina en la hemorragia activa por varices esofagogastrica
114. Comparison of somatostatin and vasopressin in the control of acute esophageal variceal hemorrhage
115. Comparison of somatostatin and vasopressin in bleeding esophageal varices
116. A randomized trial of somatostatin vs vasopressin plus nitroglycerin in the treatment of acute variceal bleeding
117. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding
118. A study of octreotide in oesophageal varices
119. Somatostatin versus Sengstaken balloon tamponade for primary haemostasia of bleeding esophageal varices
120. Controlled trial of somatostatin and balloon tamponade in bleeding esophageal varices
121. Esophageal tamponade in the treatment of bleeding varices
122. An 8-year prospective experience with balloon tamponade in emergency control of bleeding esophageal varices
123. Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices
124. Esophageal tamponade in the management of acute variceal hemorrhage
125. Controlled trial of vasopressin and balloon tamponade in bleeding esophageal varices
126. Vasopressin/nitroglycerin infusion vs esophageal tamponade in the treatment of acute variceal bleeding: a randomized controlled trial
127. Drug therapy for variceal hemorrhage
128. Sclerotherapy of varices
129. Injection sclerotherapy for esophageal varices
130. Emergency and elective endoscopic therapy for variceal hemorrhage
131. Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis: results of a randomized multicenter clinical trial
132. Endoscopic sclerotherapy v. conservative management of bleeding esophageal varices
133. Acute esophageal variceal sclerotherapy
134. Endoscopic sclerotherapy versus medical treatment for bleeding esophageal varices in patients with schistosomal liver disease
135. Controlled clinical trial of injection sclerotherapy for active variceal bleeding
136. Is sclerotherapy the first choice treatment for active oesophageal variceal bleeding in cirrhotic patients?
137. Somatostatin and urgent sclerotherapy in active esophageal variceal bleeding
138. A prospective randomized controlled trial comparing somatostatin (SMS) and injection sclerotherapy in the control of acute variceal haemorrhage: an interim report
139. A prospective randomized controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in the control of oesophageal varices
140. A prospective randomized trial comparing Somatostatin and sclerotherapy in the treatment of acute variceal bleeding
141. Octreotide infusion of emergency sclerotherapy for variceal hemmorrhage
142. Tamponade and injection sclerotherapy in the management of bleeding esophageal varices
143. Sclerotherapy after first variceal hemorrhage in cirrhosis
144. Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagogastric varices: a prospective randomized trial
145. A randomized trial of tamponade or sclerotherapy as immediate treatment for bleeding esophageal varices
146. Endoscopic sclerotherapy versus esophageal transection in Child's class C patients with variceal hemorrhage
147. Oesophageal transection versus injection sclerotherapy in the management of bleeding oesophageal varices in patients at high risk
148. Randomized trial of portacaval shunt stapling transection and endoscopic sclerotherapy in uncontrolled variceal bling
149. A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices
150. Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage
151. Endoscopic sclerotherapy as compared with endoscopic variceal ligation for bleeding esophageal varices
152. A clinical investigation of the portacaval shunt: survival analysis of the therapeutic operation
153. A controlled study of the therapeutic portacaval shunt
154. A controlled study of therapeutic portacaval shunt in alcoholic cirrhosis
155. Results of a 12-year randomized trial of portacaval shunt in patients with alcoholic liver disease and bleeding varices
156. Prospective comparative clinical trial with distal splenorenal and mesocaval shunts
157. Comparison of distal and proximal splenorenal shunts
158. Further report of a prospective randomized trial comparing distale splenorenal shunt with end-to-side portacaval shunt
159. The Emory prospective randomized trial: selective versus non-selective shunt to control variceal bleeding
160. Results of a randomized trial of end-to-side portacaval shunt and distal splenorenal shunt in alcoholic liver disease and variceal bleeding
161. Distal splenorenal vs. portalsystemic shunts after hemorrhage from varices: a randomized controlled trial
162. Partial versus total portacaval shunt in alcoholic cirrhosis
163. Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding
164. Sclerotherapy vs distal splenorenal shunt in the elective treatment of variceal hemorrage: a randomized controlled trial
165. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis
166. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding
167. Randomized trial comparing distal splenorenal shunt and sclerotherapy in the prevention of variceal rebleeding
168. A prospective randomized controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child Class A cirrhotics
169. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage
170. Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal bleeding
171. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis
172. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report
173. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial
174. Etude controlée du propranolol dans la prévention des récidives hémorragiques chez les patients cirrhotiques
175. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial
176. β-Blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial
177. Randomized controlled study of propranolol for the prevention of recurrent esophageal varices bleeding in patients with cirrhosis
178. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients
179. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy
180. Propranolol et prevention des recidives de rupture de varice oesophagienne du cirrhotique
181. Propranolol in the prevention of variceal hemorrhage in alcoholic cirrhotic patients
182. Failure of repeated injection sclerotherapy to improve long term survival after oesophageal variceal bleeding
183. Sclerotherapy after first variceal hemorrhage in cirrhosis
184. Improved survival following sclerotherapy for esophageal varices: final analysis of a controlled trial
185. Endoscopic sclerotherapy versus conservative management of bleeding esophageal varices
186. A prospective randomized controlled trial of chronic esophageal variceal sclerotherapy
187. Prospective randomized trial of long term sclerotherapy for variceal rebleeding, using the same protocol to treat rebleeding in all patients
188. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: results of a randomized multicenter clinical trial
189. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding
190. Sclerotherapy endoscopique contre propranolol aprés hemorrage par rupture de varices oesophagennes chez le cirrhotique
191. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding
192. Prevention des récidives hemorragiques chez des malades atteints de cirrhose
193. A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients
194. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy
195. Propranolol (P) versus endoscopic sclerotherapy (EPS) for the prevention of recurrent hemorrage in cirrhosis: final analysis of a randomized clinical trial
196. Endoscopic injection sclerotherapy and propranolol in the prevention of recurrent variceal bleeding
197. Endoscopic sclerotherapy versus propranolol in the elective treatment of variceal bleeding
198. Propranolol vs sclerotherapy in the prevention of variceal rebleeding: a randomized controlled trial
199. Use of propranolol to reduce the rebleeding rate during injection sclerotherapy prior to variceal obliteration
200. Propranolol in prevention of rebleeding from esophageal varices during the course of endoscopic sclerotherapy
201. Evaluation of propranolol for prevention of recurrent bleeding from esophageal varices between sclerotherapy sessions
202. Prevention of rebleeding from esophageal varices two-year follow of a prospective controlled trial of propranolol in addition to sclerotherapy
203. Propranolol reduces the rebleeding rate during injection sclerotherapy before variceal obliteration
204. Nadolol for prevention of variceal rebleeding during the course of endoscopic injection sclerotherapy: a randomized pilot study
205. Nadolol does not reduce early rebleeding in cirrhotics undergoing endoscopic variceal sclerotherapy (EVS): a multicentre randomized controlled trial
206. Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy
207. Nadolol con coadyuvante a la scleroterapia en el tratamiento electivo de la hemorragia por varices esofàgicas. Estudio randomizado y controlado
208. A prospective randomized study to evaluate propranolol in patients undergoing long-term endoscopic sclerotherapy
209. Comparison of three nonsurgical treatments for esophageal varices
210. Does elective sclerotherapy improve the efficacy of long-term propranolol for prevention of recurrent bleeding in patients with severe cirrhosis?
211. Endoscopic ligation of esophageal varices
212. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices
213. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices
214. Randomized trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices
215. Isosorbide 5-mononitrate reduces hepatic vascular resistance and portal pressure in patients with cirrhosis
216. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension
217. Oral administration of clonidine in patients with cirrhosis
218. Effects of ritanserin, a serotonin antagonist, in cirrhotic patients with portal hypertension
219. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis
220. Effects of molsidomine, a long acting venous dilator, on portal hypertension
221. Enhancement of portal pressure reduction by the association of isosorbide 5-mononitrate to propranolol administration in patients with cirrhosis
222. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis
223. Spironolactone decreases portal pressure in patients with compensated cirrhosis
224. Isosorbide-5-monoitrate versus propranolol in the prevention of first bleeding in cirrhosis
225. Expandable intrahepatic portocaval shunt stents: early experience in the dog
226. Self-expandable stainless steel braided endoprosthesis for biliary strictures
227. Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation
228. Percutaneous transjugular portosystemic shunt
229. Transjugular intrahepatic portosystemic shunt (TIPS): efficacy, complications and significance of the learning experience
230. Transjugular intrahepatic portosystemic shunts (TIPS): preliminary results in 25 patients
231. Transjugular intrahepatic portosystemic shunt (TIPS) and pathophysiology of portal hypertension (PH): endoscopic, radiologic and biochemical correlations
232. Transjugular intrahepatic portosystemic shunt (TIPS): experience with an improved technique
233. TIPS for portal hypertension and liver cirrhosis
234. Serial measurement of portal hemodynamics after partial portal decompression
235. A systematic appraisal of portacaval H-graft diameters: clinical and hemodynamic perspectives
236. Predictability and maintenance of portal flow patterns after small diameter portacaval H-grafts in man
237. Selective shunt in the management of variceal bleeding in the era of liver transplantation
238. Liver transplantation in the management of bleeding oesophageal varices